Evidence map›Paper›PMID 42574092›Full record

ArticleDrug development research2026

Targeting CDK-2 With Novel Indole-Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies.

Wagdy M Eldehna, Zainab M Elsayed, Mohamed R Elnagar, Yasser M Omar, Maha-Hamadien Abdulla, Abdulrahman M Saleh, Abdelrahman R Shalabi, Diaaeldin M Elimam, Suliman Alshamari, Mohamed Fares and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug development research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wagdy M EldehnaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.ORCID https://orcid.org/0000-0001-6996-4017
Zainab M ElsayedScientific Research and Innovation Support Unit, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.ORCID https://orcid.org/0009-0005-6913-356X
Mohamed R ElnagarDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0003-0434-2369
Yasser M OmarInstitute of Cancer Therapeutics, University of Bradford, Bradford, UK.
Maha-Hamadien AbdullaColorectal Research Chair, Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-5170-2294
Abdulrahman M SalehPostgraduate Program in Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-5153-7399
Abdelrahman R ShalabiPharmaceutical Chemistry Department, Faculty of Pharmacy, Sinai University, North Sinai, Egypt.ORCID https://orcid.org/0000-0001-9334-5187
Diaaeldin M ElimamDepartment of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Suliman AlshamariColorectal Research Chair, Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-9596-5590
Mohamed FaresSydney Pharmacy School, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-0589-3955
Haytham O TawfikDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.ORCID https://orcid.org/0000-0001-6455-5716

Funding

King Saud University (ORF-2026-344).
6 · The paper itself

Abstract

The current study devised and synthesized a novel class of pyrazole derivatives based on indole as possible inhibitors of cyclin-dependent kinase-2 (CDK-2).

Indexed as

Antineoplastic AgentsCyclin-Dependent Kinase 2IndolesProtein Kinase InhibitorsPyrazolesCell Line, TumorCell ProliferationComputer SimulationHumansMolecular Docking SimulationRoscovitineStructure-Activity RelationshipAntineoplastic AgentsCDK2 protein, humanCyclin-Dependent Kinase 2indoleIndolesProtein Kinase InhibitorsPyrazolesRoscovitineanticancer activityCDK‐2 inhibitorscell‐cycle arrestindole‐pyrazole hybridsin silico studies

Identifiers

PMID42574092
PMCPMC13456094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.